PortfoliosLab logoPortfoliosLab logo
ENTA vs. SRRK
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ENTA vs. SRRK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Enanta Pharmaceuticals, Inc. (ENTA) and Scholar Rock Holding Corporation (SRRK). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ENTA achieves a -29.80% return, which is significantly lower than SRRK's -0.57% return.


ENTA

1D
-1.86%
1M
-27.84%
YTD
-29.80%
6M
-21.93%
1Y
48.19%
3Y*
-24.76%
5Y*
-25.36%
10Y*
-7.18%

SRRK

1D
-1.13%
1M
-9.49%
YTD
-0.57%
6M
-3.20%
1Y
27.96%
3Y*
84.27%
5Y*
8.97%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

ENTA vs. SRRK - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
ENTA
Enanta Pharmaceuticals, Inc.
-29.80%174.26%-38.89%-79.77%-37.79%77.62%-31.85%-12.78%-27.44%
SRRK
Scholar Rock Holding Corporation
-0.57%1.92%129.89%107.73%-63.57%-48.82%268.21%-42.62%61.19%

Correlation

The correlation between ENTA and SRRK is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.28

Correlation (3Y)
Calculated over the trailing 3-year period

0.30

Correlation (5Y)
Calculated over the trailing 5-year period

0.33

Correlation (All Time)
Calculated using the full available price history since May 24, 2018

0.31

Fundamentals

Market Cap

ENTA:

$319.83M

SRRK:

$5.57B

EPS

ENTA:

-$2.67

SRRK:

-$3.49

PB Ratio

ENTA:

2.77

SRRK:

20.20

Total Revenue (TTM)

ENTA:

$69.21M

SRRK:

$0.00

Gross Profit (TTM)

ENTA:

$33.44M

SRRK:

-$1.27M

EBITDA (TTM)

ENTA:

-$61.85M

SRRK:

-$394.71M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ENTA vs. SRRK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ENTA
ENTA Risk / Return Rank: 6868
Overall Rank
ENTA Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
ENTA Sortino Ratio Rank: 7474
Sortino Ratio Rank
ENTA Omega Ratio Rank: 7373
Omega Ratio Rank
ENTA Calmar Ratio Rank: 6969
Calmar Ratio Rank
ENTA Martin Ratio Rank: 6666
Martin Ratio Rank

SRRK
SRRK Risk / Return Rank: 5959
Overall Rank
SRRK Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
SRRK Sortino Ratio Rank: 6161
Sortino Ratio Rank
SRRK Omega Ratio Rank: 5757
Omega Ratio Rank
SRRK Calmar Ratio Rank: 6060
Calmar Ratio Rank
SRRK Martin Ratio Rank: 6161
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ENTA vs. SRRK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Enanta Pharmaceuticals, Inc. (ENTA) and Scholar Rock Holding Corporation (SRRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ENTASRRKDifference
Sharpe ratioReturn per unit of total volatility

+0.01

Sortino ratioReturn per unit of downside risk

+0.68

Omega ratioGain probability vs. loss probability

1.24

1.14

+0.10

Calmar ratioReturn relative to maximum drawdown

1.41

0.81

+0.61

Martin ratioReturn relative to average drawdown

2.72

1.92

+0.80

ENTA vs. SRRK - Sharpe Ratio Comparison

The current ENTA Sharpe Ratio is 0.44, which is comparable to the SRRK Sharpe Ratio of 0.43. The chart below compares the historical Sharpe Ratios of ENTA and SRRK, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ENTASRRKDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.44

0.43

+0.01

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.35

0.05

-0.40

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.12

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.05

0.09

-0.14

Drawdowns

ENTA vs. SRRK - Drawdown Comparison

The maximum ENTA drawdown since its inception was -96.63%, roughly equal to the maximum SRRK drawdown of -93.15%. Use the drawdown chart below to compare losses from any high point for ENTA and SRRK.


Loading charts...

Drawdown Indicators


ENTASRRKDifference

Max Drawdown

Largest peak-to-trough decline

-96.63%

-93.15%

-3.48%

Max Drawdown (1Y)

Largest decline over 1 year

-34.30%

-34.86%

+0.56%

Max Drawdown (3Y)

Largest decline over 3 years

-83.61%

-65.21%

-18.40%

Max Drawdown (5Y)

Largest decline over 5 years

-95.62%

-88.96%

-6.66%

Max Drawdown (10Y)

Largest decline over 10 years

-96.63%

Current Drawdown

Current decline from peak

-91.24%

-35.61%

-55.63%

Average Drawdown

Average peak-to-trough decline

-49.23%

-56.44%

+7.21%

Ulcer Index

Depth and duration of drawdowns from previous peaks

17.76%

14.61%

+3.15%

Volatility

ENTA vs. SRRK - Volatility Comparison

Enanta Pharmaceuticals, Inc. (ENTA) and Scholar Rock Holding Corporation (SRRK) have volatilities of 13.36% and 13.58%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ENTASRRKDifference

Volatility (1M)

Calculated over the trailing 1-month period

13.36%

13.58%

-0.22%

Volatility (6M)

Calculated over the trailing 6-month period

35.53%

35.86%

-0.33%

Volatility (1Y)

Calculated over the trailing 1-year period

109.93%

65.55%

+44.38%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

73.36%

180.23%

-106.87%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

60.70%

157.72%

-97.02%

Dividends

ENTA vs. SRRK - Dividend Comparison

Neither ENTA nor SRRK has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ENTA vs. SRRK - Financials Comparison

This section allows you to compare key financial metrics between Enanta Pharmaceuticals, Inc. and Scholar Rock Holding Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M25.00M30.00M35.00M20222023202420252026
17.16M
0
(ENTA) Total Revenue
(SRRK) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ENTA and SRRK have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SRRK has higher volatility (13.58%) compared to ENTA (13.36%). In terms of maximum drawdown, ENTA dropped -96.63% vs SRRK's -93.15%.

ENTA currently has the higher Sharpe Ratio (0.44 vs 0.43), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ENTA and SRRK

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer